Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer

13 Dec 2017

Abstract excerpt

Neuroendocrine prostate cancer (NE PCa) is an aggressive malignancy, often presenting with advanced metastasis. We previously reported that reduction of histone marks regulated by DNMT1 following epidrug (5-Azacitidine, 5-Aza) treatment controls induction of epithelial to mesenchymal (EMT) and a cancer stem cell (CSC) phenotype, which facilitates tumorigenesis in PCa cells. Here, we use the epidrug 5-Aza as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to FOXO transcription factor regulation
Share to Mechanisms of cancer metastasis
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29236331
DOI: 10.1002/jcb.26586

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancerPMID 29236331Read ↗

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

Pharmacological targeting of EED is an effective therapeutic strategy in cellular models of incurable neuroendocrine prostate cancerSemantic proximity Read ↗

Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancerSemantic proximity Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerSemantic proximity Read ↗

The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage PlasticitySemantic proximity Read ↗

The epigenetic and transcriptional landscape of neuroendocrine prostate cancerSemantic proximity Read ↗

DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2Semantic proximity Read ↗

Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of RESTSemantic proximity Read ↗

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read ↗

The Many Faces of Neuroendocrine Differentiation in Prostate Cancer ProgressionSemantic proximity Read ↗

PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.